StockNews.com Begins Coverage on Trinity Biotech (NASDAQ:TRIB)

StockNews.com initiated coverage on shares of Trinity Biotech (NASDAQ:TRIB) in a report published on Tuesday. The firm issued a buy rating on the stock.

Trinity Biotech Trading Down 19.7 %

Shares of NASDAQ:TRIB opened at $2.78 on Tuesday. The firm’s 50 day moving average is $1.87 and its two-hundred day moving average is $2.16. Trinity Biotech has a 52 week low of $1.49 and a 52 week high of $5.50. The firm has a market capitalization of $21.18 million, a P/E ratio of -1.00 and a beta of 1.16.

Trinity Biotech (NASDAQ:TRIB) last announced its quarterly earnings results on Thursday, April 4th. The company reported ($0.68) EPS for the quarter. The business had revenue of $13.43 million for the quarter. Analysts predict that Trinity Biotech will post -2.17 EPS for the current year.

Trinity Biotech Company Profile

Trinity Biotech plc acquires, together with its subsidiaries, develops, acquires, manufactures, and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market in the Americas and Ireland. The company offers clinical laboratory products, including diagnostic tests and instrumentation, which detects infectious diseases; sexually transmitted diseases consisting of syphilis and herpes; SARS-CoV-2; and epstein barr, measles, mumps, toxoplasmosis, cytomegalovirus, rubella, varicella and other viral pathogens, as well as products for the in-vitro diagnostic testing for haemoglobin A1c used in the monitoring and diagnosis of diabetes, and identifying those who are at a risk of developing diabetes.